BOOK NOW!

Proventa International's 5th Annual

DRUG DISCOVERY BIOLOGY

STRATEGY MEETING WEST COAST USA 2023

8th May 2023, Monday | **Hard Rock Hotel San Diego**

Assessing, Choosing And Optimizing The Right Set Of Data And Methodologies To Help With Finding Effective Modalities And Techniques For Drug Discovery Biology

Featuring Industry Leaders and Decision Makers:

Susan Whitehead
President & Chief Operating Officer
PACT Pharma

Jack Reich
Chief Executive Officer
Renova Therapeutics

Prasun Mishra
CEO, **Founder, Agility Pharmaceuticals** & CEO, Founding President
American Association for Precision Medicine (AAPM)

Rishi Rakhit
Vice President, Translational Medicine
Mitokinin Inc

Kate Blease
Vice President Translational Sciences
Pfizer

Sandor Szalma
Global Head, Computational Biology
Takeda

Tove Tuntland
Senior Director Global DMPK
Ferring Pharmaceuticals

Arun Thottumkara
Director of Chemistry, Enabling Science
Odyssey Therapeutics

20 ROUNDTABLE DISCUSSIONS

5 TRACKS

2 KEYNOTE PRESENTATIONS

1 LOCATION

What Makes Our Strategy Meetings So Unique?

Proud to Partner with:

WuXi AppTec | BasePair Biotechnologies, Inc. | aragen | CONCEPT LIFE SCIENCES | Confluence Discovery Technologies | NovAliX | Selvita

Scan to register

Proventa International's Strategy Meetings are a completely unique experience.

DRUG DISCOVERY BIOLOGY
STRATEGY MEETING WEST COAST USA 2023

8th May 2023, Monday | Hard Rock Hotel San Diego

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.

Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS
These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA
Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS
The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING
Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- President / VP
- Department Head
- Other
- Team Lead
- C-Level
- Scientist
- Academia
- Manager
- Biology Specialist



Biology

- Biology
- R&D
- Drug Discovery
- Bioinformatics
- DMPK
- ADME
- Toxicology
- Structural Biology
- Pre-Clinical

Meet Investors

- Venture Capital
- Private Equity
- Large Pharma/Biotech
- Corporate Venture Capital
- Institutional
- High Net Worth
- Family Office/Private Wealth
- Government Organisation/ Sovereign Wealth Fund
- Angel

Facilitator Faculty

Steve Smith
Technical Director of in vivo Pharmacology
WuXi AppTec

Arun Thottumkara
Director of Chemistry, Enabling Science
Odyssey Therapeutics

Beth J Hoffman
Founder & CEO
Origami Therapeutics

Kate Blease
Vice President Translational Sciences
Pfizer

Han Xu
SVP, Head of Biology
Velia Therapeutics

Heather Estrella
Associate Scientific Director
Takeda San Diego, Inc.

Leo Kirkovsky,
Director Clinical Assay
Pfizer

Jack Reich
CEO
Renova Therapeutics

Kristy D. Bruse
Sr. Director, Toxicology
Ferring Pharmaceuticals

Prasun Mishra
CEO, Founder, **Agility Pharmaceuticals** and CEO, Founding President, **American Association for Precision Medicine (AAPM)**

Rishi Rakhit
Vice President, Translational Medicine
Mitokinin Inc

Robert T. Fremeau, Jr.
Founder and Chief Scientific Officer
Brainstorm Therapeutics, Inc.

Sandor Szalma
Global Head, Computational Biology
Takeda

Susan Whitehead
President & Chief Operating Officer
PACT Pharma

Tove Tuntland
Senior Director Global DMPK
Ferring Pharmaceuticals

Yuhua Ji
VP of Drug Discovery
Grace Science

How Has Our **STRATEGY MEETINGS** Benefit The Life Science Industry

> *The meeting was excellent. Discussions were great and trying to get everyone around the table to participate made for great idea sharing."*
>
> **Joseph Mancini —**
> *Head of Pharmacology*, AdMare Bioinnovations

> *It was a pleasure for me to participate. I love this series. Please keep it up!"*
>
> **Zhihua Sui —**
> *CSO, Head of Research & Preclinical Development*, Proteovant Therapeutics

2023 Sponsors

CO-HOST SPONSORS

WuXi **AppTec** provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.
http://www.wuxiapptec.com

Base Pair Biotechnologies is based just 10 miles south of the Houston, Texas Medical Center. Our team of 11 scientists has a combined 50+ person-years of experience in developing aptamers. Base Pair owns the sole worldwide rights to patents for multiplexed aptamer discovery. We have the capability to select aptamers to up to 30 protein, peptide, or small molecule targets in true competitive, multiplexed fashion. The resulting aptamers are therefore more specific for their particular targets. Using this technology, we have completed contracts from the National Cancer Institute, the CDC, and many large pharma and biotech firms and can serve as an excellent partner to help achieve your drug discovery and validation needs.

Aragen Life Sciences is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. We offer end-to-end integrated or standalone solutions for small and large molecules. Established in 2001, we now operate through our network of sites located globally with a team of 3700+ scientists and 475+ PhDs. Our expertise and experience have enabled over 450+ customers in advancing their research programs from discovery through commercialization. Aragen's innovative mindset, infrastructure, flexible business models have enabled us to serve large pharma or biotech, agrochemical, animal health and performance chemical industries globally. All our facilities conform to stringent regulatory standards. Our infrastructure has a built-up area of 1.2 million square feet, housing chemistry and biology labs, AAALAC-accredited animal houses, analytical labs, formulation development labs, kilo labs, pilot plants and manufacturing facilities. Aragen has been inspected by all leading regulatory agencies of the world, including USFDA, WHO, PMDA, EDQM and EMEA. Aragen has submitted its letter of intent to the Science Based Targets initiative (SBTi) and is part of a growing list of organizations that are committed to setting emission reduction targets in line with the Paris Agreement to limit global warming. It is also a signatory to the GRI South Asia Charter on Sustainability Imperatives, a framework that helps to realize the 17 Sustainable Development Goals (SDGs) defined by the United Nation. We are proud to be a Great Place to Work® (GPTW) certified company for the third consecutive year in 2022. This recognition confirms our High-Trust, High-Performance Culture™ and places us among 'companies with the best culture' to work with. For more details, visit www.aragen.com

Biography TBC

Biography TBC

KEY OPINION LEADERS

Agenda at a Glance

DRUG DISCOVERY BIOLOGY
STRATEGY MEETING WEST COAST USA 2023
8th May 2023, Monday | Hard Rock Hotel San Diego

TIME PT	TRACK 1 TARGET IDENTIFICATION & HIT VALIDATION	TRACK 2 DMPK / ADME & TOXICOLOGY	TRACK 3 IN VIVO AND IN VITRO PHARMACOLOGY	TRACK 4 IN SILICO BIOLOGY	TRACK 5 STRATEGIC PARTNERSHIPS & COLLABORATIONS
08:00 - 08:30	BREAKFAST & REGISTRATION				
08:30 - 09:00	OPENING KEYNOTE PRESENTATION RNA Targeting Outside of Vaccines				
09:00 - 10:00	**Leveraging the Power of Multi-Omics in Drug Discovery: Maximizing the Potential in Target Identification and Safety Profiling** Beth J Hoffman, *Founder & CEO*, Origami Therapeutics	**How to Leverage AI and Clinical Data to Better Predict Toxicology for Future Drug Discovery** Heather Estrella, *Associate Scientific Director*, Takeda San Diego, Inc.	**In Vivo and In Vitro Pharmacology Advances to Maximize Preclinical Drug Discovery** Kate Blease, *Vice President Translational Sciences*, Pfizer	**Lipid GPCRS Structural And Computational Approach: Advantages, Challenges, Limitations And New Modalities In Drug Discovery** Arun Thottumkara, *Director of Chemistry, Enabling Science*, Odyssey Therapeutics	**Why Integrating Deep Scientific Expertise Matched With Operational And Business Strategy Is Key For Attracting Investment In Early-Stage Drug Discovery** Susan Whitehead, *President & Chief Operating Officer*, PACT Pharma
10:00 - 10:10	REFRESHMENT BREAK				
10:10 - 10:30	NETWORKING / 1-1 MEETINGS				
10:30 - 10:50	NETWORKING / 1-1 MEETINGS				
10:50 - 11:10	NETWORKING / 1-1 MEETINGS				
11:10 - 12:10 SOLUTION	**Selection Of Appropriate Modalities And Hit ID Strategies For Fic Targets** SPONSOR	**Predictive Model For Preclinical ADMET: New Modalities, Performance And Applications** SPONSOR	**Understanding and Improving Preclinical Therapeutic Dosing for Successful Clinical Trials** Steve Smith, *Technical Director of in vivo Pharmacology*, WuXi AppTec WUXI APPTEC 药明康德 WuXi AppTec	**Novel Drug Modality Update: RNA-Targeting Small Molecules** SPONSOR	**Strategic Guide To Maximize Value: Identifying The Ideal Partner, Formulating The Best Negotiation Strategy And Deal Structure** SPONSOR
12:10 - 13:10	NETWORKING LUNCH				
13:10 - 13:40	AFTERNOON KEYNOTE PRESENTATION Tmod cell therapy with NOT-gate Boolean logic distinguishes tumor from normal cells in autologous and allogeneic treatment PRESENTER: Han Xu, *SVP, Head of Biology*, Velia Therapeutics				
13:40 - 14:40	**Phenotypic Assays And Platform Essential Characteristics Needed For Wide Usage In The Drug Discovery Process** Prasun Mishra, *CEO, Founder*, Agility Pharmaceuticals *and CEO, Founding President*, American Association for Precision Medicine (AAPM)	**Recent Advances In ADMET/DMPK Strategies To Improve Prediction In Drug Discovery** Tove Tuntland, *Senior Director Global DMPK*, Ferring Pharmaceuticals	**Improving Translatable Pre-Clinic Models In-Vitro & In-Vivo Pharmacology for Better Characterization of Properties and Drug Leads** Rishi Rakhit, *Vice President, Translational Medicine*, Mitokinin Inc	**Leveraging AI For Drug Discovery Through Different Modalities** Sandor Szalma, *Global Head, Computational Biology*, Takeda	**Navigating The Constantly Changing Market To Raise Funds And Refine R&D Strategy** Jack Reich, *CEO*, Renova Therapeutics
14:40 - 14:50	REFRESHMENT BREAK				
14:50 - 15:10	NETWORKING / 1-1 MEETINGS				
15:10 - 15:30	NETWORKING / 1-1 MEETINGS				
15:30 - 15:50	NETWORKING / 1-1 MEETINGS				
15:50 - 16:50	**Accelerating Treatments for Complex Neurologic and Neurodegenerative Disorders: Leveraging an understanding of human disease biology to accelerate and de-risk CNS drug discovery and development** Robert T. Fremeau, Jr., *Founder and Chief Scientific Officer*, Brainstorm Therapeutics, Inc.	**Predictive Model For Preclinical ADMET: New Modalities, Performance And Applications** Kristy D. Bruse, *Sr. Director, Toxicology*, Ferring Pharmaceuticals	**Developing And Improving Preclinical Dose Projection And Prediction For Further Clinical Studies** Han Xu, *SVP, Head of Biology*, Velia Therapeutics	**How AI applications such as GPT can help in drug discovery and development** Leo Kirkovsky, *Director Clinical Assay*, Pfizer	**Maximizing Capital Efficiency By Balancing Internal Capabilities And External CRO's** Yuhua Ji, *VP of Drug Discovery*, Grace Science
16:50 - 17:50	DRINKS & CANAPES RECEPTION				

Event Day | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.

08:30 - 09:00 PT **OPENING KEYNOTE PRESENTATION**

RNA Targeting Outside of Vaccines

Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

13:10 - 13:40 PT **AFTERNOON KEYNOTE PRESENTATION**

Tmod cell therapy with NOT-gate Boolean logic distinguishes tumor from normal cells in autologous and allogeneic treatment

On-target/off-tumor toxicity has been one of the challenges for adoptive cell therapy against solid tumors. Loss of heterozygosity (LOH) is commonly observed in many solid tumor types. To exploit such irreversible genetic difference between tumor and normal cells, we have developed a cell therapy that utilizes a combination of tumor-specific target and HLA deletion to focus cytotoxicity on cancer cells. The engineered T cells contain a dual-receptor system (Tmod): (i) an activating CAR that binds tumor-specific targets and (ii) an inhibitory LIR-1 based receptor (blocker) that binds HLA-A*02. Tmod cells have comparable potency to CAR-T cells but have striking selectivity for A*02(-) tumor over A*02(+) normal cells in vitro and in vivo. Examples of Tmod therapies with successful preclinical results for autologous and allogeneic treatment will be discussed. For instance, carcinoembryonic antigen (CEA)-targeting immunotherapies have caused severe toxicity in clinical trials due to its expression on normal cells even though it is an attractive tumor-associated antigen with overexpression in a variety of solid tumor types, including cancers of the lung, colon, and pancreas. To overcome this hurdle, we developed CEA Tmod by pairing a CEA-specific CAR (activator) with an HLA-A*02-specific blocker. CEA Tmod cells are designed to kill tumor cells with LOH at the HLA-A*02 locus while protecting normal cells. In addition, the blocker module is able to block the activation of endogenous TCRs triggered by HLA mismatches, which can be utilized to control graft-versus-host disease (GvHD) for allogeneic cell therapy. To further develop the system into an off-the-shelf therapy, HLA expression in the adopted Tmod cells is knocked down by a B2M-targeting shRNA to minimize rejection by the host T cells. Preclinical data for Tmod cells will be discussed which illustrate their advantages in differentiating tumor vs. normal target cells and their potential for both autologous and allogeneic treatment in the future.

Han Xu
SVP, Head of Biology
Velia Therapeutics

ABOUT THE SPEAKER
Han Xu is an experienced executive and scientist in the biotech industry with a focus on therapeutic and translational science. Currently, she serves as the SVP, Head of Biology at Velia. Prior, she served as a Vice President at A2 Biotherapeutics. At A2 Bio, she has overseen the development of multiple preclinical and clinical programs, including the company's first autologous clinical candidate, and its first allogeneic program developed in collaboration with Merck. Previously, she worked at Amgen, Inc. in various leadership positions, leading multiple projects from early development to preclinical stage, and implementing cutting-edge technologies to streamline target validation and discovery.

Event Day

TRACK 1

Target Identification & Hit Validation

Improving efficiency in finding novel therapeutic targets continues to be an immediate priority and hurdle in the pharma and biotech industry. This track aims to explore the undruggable space for utilizing AI/ML, optimizing target identification pathways and many more. How can we ensure the next druggable target frontier stays viable?

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 PT ROUNDTABLE 1

Leveraging the Power of Multi-Omics in Drug Discovery: Maximizing the Potential in Target Identification and Safety Profiling

- What are the most effective ways to address target identification? and where are the pitfalls?
- Where to start? Is there an ideal flow scheme for target identification? How much data do you need to make a multi-omits approach instructive?
- When do you start to address safety profiling and what are the most valuable or go/no-go methodologies?
- When do you need single cell multi-omics and when is global multi-omics sufficient?

Beth J Hoffman
Founder & CEO
Origami Therapeutics

ABOUT THE SPEAKER
At Origami Therapeutics, Dr. Hoffman is creating a new approach to discovering curative medicines for neurodegenerative diseases. Prior to Origami, she was a Research & Development executive at Vertex Pharmaceuticals, Amgen and Eli Lilly & Co. She made major contributions to >30 programs that advanced to clinical trials and to four marketed drugs for Cystic Fibrosis (Kalydeco, Orkambi, Symdeco, Trikafta). Dr. Hoffman received her A.B. in Molecular Biology from Wellesley College and a Ph.D. in Cell Biology from the Johns Hopkins University. Dr. Hoffman serves on the Board of Directors for Biofrontera Inc. (NASDAQ: BFRI), the Scientific Advisory Board for the Tau Consortium and the National Board of Trustees for the Huntington's Disease Society of America (HDSA)

10:00 - 11:10 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT SOLUTION FOCUS ROUNDTABLE 2

Selection Of Appropriate Modalities And Hit ID Strategies For Fic Targets

Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

12:10 - 13:10 PT NETWORKING LUNCH

13:10 - 13:40 PT AFTERNOON KEYNOTE PRESENTATION
See Page 6

13:40 - 14:40 PT ROUNDTABLE 3

Phenotypic Assays And Platform Essential Characteristics Needed For Wide Usage In The Drug Discovery Process

- What are the essential characteristics of phenotypic assays for wide usage in drug discovery
- How can phenotypic assays be made more relevant to the diseases or processes being studied
- What are the advantages and limitations of using cost-effective phenotypic assays in drug discovery
- How can phenotypic assays be integrated into the drug discovery process

Prasun Mishra
CEO, Founder, Agility Pharmaceuticals
CEO, Founding President, American Association for Precision Medicine (AAPM)

ABOUT THE SPEAKER
Dr. Prasun Mishra is a leading life science, technology, and healthcare thought leader and an Impact Investor. He is a scientist with numerous publications/ patents to his credit. He has contributed to developing several drugs and combinations in trials and approved and has over 40 prestigious awards and over 35 keynote talks & invited lectureships. During his distinguished career, he served the pharma giant Genentech, Roche, Rutgers University and NCI, NIH, DHHS, U.S. Government. He is a Founding Partner of GSIF: Global Sustainability Impact Fund LLC. He also serves on the executive team of the Global Fund for Sustainable Development (GFSD): The United Nations SDGs Implementation Program.

14:40 - 15:50 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

15:50 - 16:50 PT ROUNDTABLE 4

Accelerating Treatments for Complex Neurologic and Neurodegenerative Disorders: Leveraging an understanding of human disease biology to accelerate and de-risk CNS drug discovery and development

- Patient derived brain organoids are a powerful platform for human-first CNS drug discovery
  - Reproducibly capture disease pathophysiology in a high throughput format
  - Drive compound discovery with clinically translatable disease endpoints
  - Amenable to both phenotypic and target-based screening
  - Rapid discovery of first and/or best in class targets and NCE therapeutic candidates
- Redefine CNS disease by stratifying patient subgroups based on molecular, functional and clinical heterogeneity
  - Computational genomics and transcriptomics
  - Biomarker discovery
  - Personalized brain organoids
- Robust multiparametric data analysis pipeline
  - Identify and differentiate compounds acting at distinct cellular processes
  - Rank order hits and leads based on potency, efficacy and safety in the same organoid

Robert T. Fremeau, Jr.
Founder and Chief Scientific Officer
Brainstorm Therapeutics, Inc.

ABOUT THE SPEAKER
Robert T. Fremeau, Jr., Ph.D. is an experienced R&D leader with 20+ years' experience in academia and industry. He is an accomplished scientist and biotech entrepreneur with a demonstrated history of scientific innovation and program leadership at the intersection of target validation, translation and clinical development. He is the founder and CSO of BrainStorm Therapeutics a biotech startup company translating the promise of patient-derived brain organoid disease models into transformative medicines for neurodegenerative disorders.

16:50 - 17:50 PT DRINKS & CANAPES RECEPTION

Event Day

TRACK 2

DMPK / ADME & Toxicology

A key idea in biology is that structure, to a large extent, dictates function. The rapid development of sensitive biophysical methods and emerging technologies that interrogate compound properties and mechanisms of action is transforming drug discovery.

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 PT ROUNDTABLE 1

How to Leverage AI and Clinical Data to Better Predict Toxicology for Future Drug Discovery

- AI in toxicology in early hazard identification prediction
- Translatability from non-clinical studies to clinic (and back)
- Dose makes the poison – how to incorporate exposure/duration into toxicity prediction
- Modality risk considerations AI helps to inform

Heather Estrella
Associate Scientific Director
Takeda San Diego, Inc.

ABOUT THE SPEAKER
Heather has over 20 years of experience in the pharmaceutical industry in both large pharma (Pfizer, Takeda) and small biotech spanning multiple modalities, including small molecules, oligonucleotides and antibodies. Her background is in computational biology from Johns Hopkins University and her career has focused on supporting pharmacology from target and patient identification to non-clinical toxicology. She is currently a Discovery Toxicologist at Takeda Pharmaceuticals where she is using bioinformatics to assess target and modality risks. She provides actionable biological insight around hazard identification to project teams and toxicologists, as well as retrospective assessment for adverse phenotypes.

10:00 - 11:10 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT SOLUTION FOCUS ROUNDTABLE 2

Recent Advances In ADMET/DMPK Strategies To Improve Prediction In Drug Discovery

Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

12:10 - 13:10 PT NETWORKING LUNCH

13:10 - 13:40 PT AFTERNOON KEYNOTE PRESENTATION
See Page 6

13:40 - 14:40 PT ROUNDTABLE 3

Recent Advances In ADMET/DMPK Strategies To Improve Prediction In Drug Discovery

In this section, we will review key advances and remaining challenges to improve ADMET/DMPK predictions in drug discovery. This includes transporter-mediated drug disposition and elimination, clearance, design principles that can minimize drug-drug interactions, and human dose predictions.

- The importance of membrane transporters in drug disposition, efficacy, and safety, and interplay with metabolic processes is recognized.
- Prediction of human cytochrome P450 (CYP)-mediated drug clearance is increasingly accurate due to the availability of high-quality reagents including human liver microsomes and human hepatocytes.
- Drug tissue distribution, DDI liability and non-CYP elimination pathways are important considerations for the accuracy of predictions.
- Dramatic increases in investments on new modalities such as peptides and antibody-drug conjugates necessitated further innovations in bioanalytical and experimental tools for the characterization of their ADME properties.

Tove Tuntland
Senior Director Global DMPK
Ferring Pharmaceuticals

ABOUT THE SPEAKER
Tove Tuntland, Ph.D., heads the Global Drug Metabolism and Pharmacokinetics (DMPK) department at Ferring Pharmaceuticals. Tove joined Ferring in 2021 to oversee a global group that supports preclinical bioanalytical-, ADME-, DMPK- and PK/PD studies in Reproductive Medicine & Maternal Health. She began her career at Pfizer in La Jolla, CA, where she worked for 6 years in discovery and development of antiviral drugs. In 2002 she moved to Novartis Pharmaceuticals in San Diego to build a DMPK group that supported programs in oncology, immunology, infectious and metabolic diseases.

14:40 - 15:50 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

15:50 - 16:50 PT ROUNDTABLE 4

Predictive Model For Preclinical ADMET: New Modalities, Performance And Applications

- Customizing Small molecule screening funnels- “using the right assays not all assays
- Using In silico and in vitro assays for Predictive Safety Assessment (Secondary Pharmacology & Toxicology)
- Integration of DMPK and Toxicology representatives (ADMET) in Core Teams. “How to work more efficiently (and cost effectively) with the Lead Chemist and Biologist/Pharmacologist. Examples on how Toxicologist and DMPK representatives assist the Project Team

Kristy D. Bruse
Sr. Director, Toxicology
Ferring Pharmaceuticals

ABOUT THE SPEAKER
Kristy has served as Director/Sr. Director of Discovery Toxicology at Gossamer Bio and Ferring as the key Discovery Toxicologist to drug discovery teams, providing scientific expertise and developed/ implemented toxicity screening (front-loading) strategies. At Gossamer Bio she also supported two IND packages. She has over 40 years of Experience in Drug Discovery and Early Safety Assessment and is a motivated and talented Safety Pharmacologist and Toxicologist who brings current knowledge and techniques to the complex business of preclinical small molecule drug development. Dr. Bruse (maiden name: Lake) obtained post-doctoral training in gene therapy (1997-2001), her Ph.D. in cardiovascular regulation via cannabinoid receptors 1996) in Pharmacology and Toxicology, her M.S. (1986) focused on CNS-mediated cardiovascular regulation, and her B.S. focusing on animal physiology/pre-veterinary medicine.

16:50 - 17:50 PT DRINKS & CANAPES RECEPTION

Event Day

TRACK 3

In Vivo and In Vitro Pharmacology

A primary source of drug candidate trial failure is attributed to inadequate efficacy and safety profiles. This track serves to highlight key topics and pressing challenges within the areas of drug metabolism, biotransformation and drug toxicity.

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 PT ROUNDTABLE 1

In Vivo and In Vitro Pharmacology Advances to Maximize Preclinical Drug Discovery

- Leveraging in vitro and in vivo systems to improve translational predictability
- Advances in in vivo models to more accurately reflect the patient
- What are the advances in in vitro systems that emerging to minimize animal usage

Kate Blease
Vice President Translational Sciences
Pfizer

ABOUT THE SPEAKER
Kate Blease is Vice President of Translational Sciences in the Oncology Research and Development group at Pfizer. Kate leads a group of 70 scientists bridging the preclinical to clinical gap, using bench science to maximize clinical benefit for oncology patients. Kate studied Pharmacology at the University of Bath and Imperial College London for her bachelor's and PhD, respectively and completed her postdoctoral training at University of Michigan. Prior to joining Pfizer, Kate spent 17 years at Celgene in inflammation, immunology, fibrosis and oncology drug discovery and development. She has contributed to over 20 successful IND filings and several drug approvals.

10:00 - 11:10 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT SOLUTION FOCUS ROUNDTABLE 2

Understanding and Improving Preclinical Therapeutic Dosing for Successful Clinical Trials

- Current state of the art pharmacology models: Accuracy and predictive value of in vitro and in vivo models
- Improving *in vitro* and *in vivo* preclinical models to accelerate the target discovery to IND path
- Identification of biomarkers to accurately monitor disease progression and therapeutic efficacy

Steve Smith
Technical Director of in vivo Pharmacology
WuXi AppTec

ABOUT THE SPEAKER
Dr. Smith is a Technical Director – in vivo Pharmacology at WuXi AppTec. He has designed and conducted research in therapeutic areas spanning oncology, metabolic diseases, neurodegenerative diseases, inflammatory diseases, and immunology, as well as built *in vivo* and *in vitro* model systems for target discovery and validation, and therapeutic area research. Prior to WuXi AppTec Steve led research programs at Zogenix Inc., FivePrime Therapeutics, Caliper Life Sciences, Bayer Biotechnology, and Parke-Davis Laboratory of Molecular Genetics. Steve earned B.S. in Biology from Beloit College, M.S. and Ph.D. in Microbiology from North Carolina State University, and was a postdoctoral fellow at the Gladstone Institute of Cardiovascular Disease.

12:10 - 13:10 PT NETWORKING LUNCH

13:10 - 13:40 PT AFTERNOON KEYNOTE PRESENTATION
See Page 6

13:40 - 14:40 PT ROUNDTABLE 3

Improving Translatable Pre-Clinic Models In-Vitro & In-Vivo Pharmacology for Better Characterization of Properties and Drug Leads

- How well does the cellular or animal model reflect target biology, and how well does it model human disease?
- How well does the animal model being used recapitulate pathway and ADME biology relevant to human disease?
- At what point should target coverage modelling be used and combined with PK to predict required efficacy?
- What are the advantages and disadvantages of using the same or different species for target-engagement, efficacy, PK, and preclinical tox studies?

Rishi Rakhit
Vice President, Translational Medicine
Mitokinin Inc

ABOUT THE SPEAKER
Rishi has led large and small molecule discovery and translation efforts at Denali Therapeutics, Achaogen, and Mitokinin, resulting in multiple successful partnerships and clinical molecules. He also pioneered structure-guided antibody design which resulted in the development of conformation-specific antibodies targeting SOD1 and TTR which are now in early and late clinical studies.

14:40 - 15:50 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

15:50 - 16:50 PT ROUNDTABLE 4

Developing And Improving Preclinical Dose Projection And Prediction For Further Clinical Studies

- Understanding the commonalities and differences in dose justification for small molecule, protein, and adoptive cell therapies
- Exploring the optimal use of animal models to predict dosage in CAR-T therapy
- The significance of benchmark molecules in determining dosage for therapeutic agents

Han Xu
SVP, Head of Biology
Velia Therapeutics

ABOUT THE SPEAKER
See page 6 for her biography.

16:50 - 17:50 PT DRINKS & CANAPES RECEPTION

Event Day

TRACK 4

In Silico Biology

The utility of computational methods is widely used in various stages of drug discovery and development. From aiding target ID & validation, limiting the use of animal models in pharmacology to aiding rational drug design, this track will explore novel approaches and application of in silico techniques to maximize productivity towards clinical success.

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 PT ROUNDTABLE 1

Lipid GPCRS Structural And Computational Approach: Advantages, Challenges, Limitations And New Modalities In Drug Discovery

- What structural and computational tools are enabling successful drug discovery against GPCRs? What are the limitations of this technology?
- What hit finding approaches and assay types are critical for a successful GPCR drug discovery program?
- How does human genetics fit into your GPCR target selection criteria?
- What in vivo models have you seen to be highly translatable to clinical success for GPCR targets?

Arun Thottumkara
Director of Chemistry, Enabling Science
Odyssey Therapeutics

ABOUT THE SPEAKER
Arun Thottumkara, PhD is a Director of Chemistry at Odyssey Therapeutics. There, he leads project teams in oncology and immunology. Arun has broad experience growing and leading successful teams in small molecule drug discovery; teams he has led and been a part of have advanced six molecules into clinical investigation. Prior to Odyssey, Arun led teams at Denali Therapeutics, focusing on small molecule therapeutics for neurodegenerative diseases. He began his drug discovery career as an early employee at Revolution Medicines. Arun received an A.B. in Chemistry from Harvard University and a Ph.D. in chemistry from Stanford University.

10:00 - 11:10 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT SOLUTION FOCUS ROUNDTABLE 2

Novel Drug Modality Update: RNA-Targeting Small Molecules

Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

12:10 - 13:10 PT NETWORKING LUNCH

13:10 - 13:40 PT AFTERNOON KEYNOTE PRESENTATION
See Page 6

13:40 - 14:40 PT ROUNDTABLE 3

Leveraging AI For Drug Discovery Through Different Modalities

- New modalities opening up opportunities to drug previously un-druggable targets. How do we re-evaluate "old" targets?
- Successes of applying ML/AI for selecting or triaging targets; need for new "druggability" rules?
- How we generate data for developing effective ML/AI models for alternative modality drug candidates?
- Optimizing efficacy - what can we learn from recent advances in ML/AI applied to small molecule drug discovery?
- Beyond efficacy – application of ML/AI to modality specific preclinical development and translational questions

Sandor Szalma
Global Head, Computational Biology
Takeda

ABOUT THE SPEAKER
Sándor Szalma is Global Head of Genetics and Systems Biology in Takeda Pharmaceuticals. He is heading a team of human geneticists, computational biologists, and machine learning experts carrying out genomic natural history and genotype-phenotype relationship studies, target de-risking, OMICS computational analysis and patient stratification modeling. Prior to joining Takeda, he held positions in data science and informatics in Janssen/J&J. After postdoctoral positions in Syracuse University and J.W. Goethe Universität, Frankfurt, he worked at Biosym/MSI/Accelrys. He is the author of more than 50 scientific publications and two patents. He received his doctoral degree in physical organic chemistry from A. Szent-Györgyi Medical University in Szeged, Hungary.

14:40 - 15:50 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

15:50 - 16:50 PT ROUNDTABLE 4

How AI applications such as GPT can help in drug discovery and development

- How can AI help identify new drug targets and drug candidates by analyzing large amounts of data and identifying patterns that may be difficult for humans to detect.
- AI can help streamline the drug development process by reducing the time and cost required for laboratory experiments and clinical trials
- AI can assist in personalized medicine by analyzing patient data and identifying which treatments are most likely to be effective for specific individuals.
- Challenges:
  - Limited data availability due to confidentiality and privacy concerns or the complexity of the data.
  - Ethical considerations, including issues around data privacy, informed consent, and bias, that need to be addressed to ensure the benefits of AI in drug discovery are realized without compromising ethical standards.

Leo Kirkovsky
Director Clinical Assay
Pfizer

ABOUT THE SPEAKER
Dr. Kirkovsky received his PhD degree in Organic Chemistry from Moscow State University and completed postdoctoral training in prostate cancer drug development at the University of Tennessee. Then he joined Biogen's DMPK department. In 2002, Dr. Kirkovsky joined Anadys Pharmaceutical as a Head of DMPK group supporting small molecule drug candidates for HCV and oncology indications. In 2007, he joined Pfizer as a Head of DMPK group supporting small molecule drug candidates for inflammation projects. Since 2010, Dr. Kirkovsky works in Clinical Assay Group (CAG) in Pfizer supporting small molecule, ADC and Nanoparticle clinical programs in oncology and anti-infectives.

16:50 - 17:50 PT DRINKS & CANAPES RECEPTION

Event Day

TRACK 5

Strategic Partnerships & Collaborations

The pharma and biotech sector continues to seek ways to address challenges in R&D productivity, spending cuts and volatile market conditions. Strategic partnerships and alliances have grown in importance to reduce cost, share risks and rewards while maximizing learning opportunities resulting from successful collaborations.

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 PT ROUNDTABLE 1

Why Integrating Deep Scientific Expertise Matched With Operational And Business Strategy Is Key For Attracting Investment In Early-Stage Drug Discovery

- Challenges
  - The need for significant investment in research and development before clinical trials
  - The complexity of drug development and regulatory requirements
  - The importance of balancing scientific rigor with operational and business efficiency
- What is the optimal balance between investment in research and development and managing operational costs
- How can we develop a clear and effective business strategy that aligns with our scientific goals and priorities
- What are the most effective ways to communicate the scientific, operational, and business aspects of our drug discovery program to potential investors
- How can we demonstrate the value of our program to potential investors, given the high failure rate and long development timelines of drug candidates

Susan Whitehead
President & Chief Operating Officer
PACT Pharma

ABOUT THE SPEAKER
Susan Whitehead is the President & COO of PACT Pharma, whose mission is to harness a patient's own immune system to fight their cancer. Susan has spent much of her career working at start-up biotech organizations leading teams and overseeing operations. Susan is passionate about creating greater health equity — from the lab to the clinic to the population served. In keeping with this principle, PACT Pharma is currently developing an HLA inclusive platform to treat patients of all ethnicities battling HPV+ cancers.

10:00 - 11:10 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT SOLUTION FOCUS ROUNDTABLE 2

Strategic Guide To Maximize Value: Identifying The Ideal Partner, Formulating The Best Negotiation Strategy And Deal Structure

Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

12:10 - 13:10 PT NETWORKING LUNCH

13:10 - 13:40 PT AFTERNOON KEYNOTE PRESENTATION
See Page 6

13:40 - 14:40 PT ROUNDTABLE 3

Navigating The Constantly Changing Market To Raise Funds And Refine R&D Strategy

Different approaches in raising funds and R&D strategies for :

- Start-up companies
- Large companies
- Small companies

Jack Reich
CEO
Renova Therapeutics

ABOUT THE SPEAKER
Jack Reich is a highly acclaimed serial entrepreneur and trailblazer in the biotechnology industry. With years of experience as a Chairman and Chief Executive Officer, he has a proven track record of success. Jack played a pivotal role in the founding of Gensia and co-founded Viagene, the first gene therapy company, and Collateral Therapeutics, the first company dedicated to cardiovascular gene therapy. In 2009, he co-founded Renova Therapeutics. He was named Entrepreneur of the Year by Washington & Jefferson College in 2016. Jack has exceptional skills in areas such as Medical Devices, Molecular Biology, Biotechnology, Mergers & Acquisitions (M&A), and Brand Licensing. He holds a Ph.D. in International Pharmaceutical Management from Temple University's Fox School of Business and Management and is highly adept at business development.

14:40 - 15:50 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

15:50 - 16:50 PT ROUNDTABLE 4

Maximizing Capital Efficiency By Balancing Internal Capabilities And External CRO's

- What are the main benefits and risks for outsourcing key project activities, including assay development, compound screening, target validation and in vivo studies?
- What are key influencing factors in your decision to build in-house capability instead of outsourcing?
- Is it more effective to work with "one-stop shop" CROs?
  - For example, do you prefer to screen and test compounds at the same CRO as the one who does the medicinal chemistry versus perform two activities at two different CROs?
- What are key attributes for a successful outsourcing? How can one improve the effectiveness and productivity of working with external CROs?

Yuhua Ji
VP of Drug Discovery
Grace Science

ABOUT THE SPEAKER
Yuhua Ji, Ph.D, has broad experiences in drug discovery and development. She has a proven track record of building team from the ground up. She led and contributed to over ten development candidates and IND-filings. Dr. Ji has extensive expertise in medicinal chemistry, CMC and preclinical development of small molecules. She is the principal inventor of revefenacin and named as the inventor on over 100 patents and the author of over 20 publications. Currently, she is VP of drug discovery at Grace Science. Previously, Dr Ji was the head of Medicinal Chemistry at Zai Lab and IND director at Virogin Biotech. During her years at Path, She led discovery chemistry and CMC, and supported several clinical development programs. She led the discovery and early development of YUPELRITM at Theravance. She spent the first 10 years of her career at Hoffmann La-Roche and was a visiting scientist at Genentech. Dr. Ji obtained Ph.D in organic chemistry and Biological Chemistry from Université de Louis Pasteur de Strasbourg.

16:50 - 17:50 PT DRINKS & CANAPES RECEPTION

DRUG DISCOVERY BIOLOGY

STRATEGY MEETING WEST COAST USA 2023

8th May 2023, Monday Hard Rock Hotel San Diego

Hotel & Venue

Hard Rock HOTEL SAN DIEGO

Hard Rock Hotel San Diego

You're the main act in San Diego. At Hard Rock Hotel, we immerse you in our musical amenities, world-class service, and intoxicating location in

HOTEL DISCOUNTED RATE: **$299 USD** only

BOOK NOW!
We only have limited rooms available!

Hotel Details > Map & Directions >




OUR FACE-TO-FACE MEETING IN MAY 2023

Strategy Meeting San Diego, Boston & Princeton USA

MAY 2023

San Diego - US West Coast
08th - Drug Discovery Biology Strategy Meeting
09th - Medicinal Chemistry Strategy Meeting
10th - Oncology Strategy Meeting
11th - Clinical Operations Strategy Meeting

MAY 2023

Boston/Cambridge MA - US East Coast
17th - Regulatory Affairs Strategy Meeting
18th - Chemistry, Manufacturing and Controls Strategy Meeting

MAY 2023

Princeton New Jersey - US East Coast
23rd - Drug Discovery Biology Strategy Meeting
24th - Medicinal Chemistry Strategy Meeting
25th - Clinical Operations Strategy Meeting

Visit us on our website to know more about our meetings
www.proventainternational.com